Education
About Us
Working with TipRanks
Follow Us
EyePoint Pharmaceuticals Inc (EYPT)
NASDAQ:EYPT
EYPT Stock Chart & Stats
$18.00
$0.01(0.11%)
At close: 4:00 PM EST
$18.00
$0.01(0.11%)
Day’s Range― - ―
52-Week Range$3.91 - $19.11
Previous CloseN/A
Volume354.62K
Average Volume (3M)1.51M
Market Cap
$1.52B
Enterprise Value$1.44B
Total Cash (Recent Filing)$204.02M
Total Debt (Recent Filing)$21.30M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
May 06, 2026EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding82,787,220
10 Day Avg. Volume2,464,686
30 Day Avg. Volume1,507,318
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)1.25
Price to Sales (P/S)9.69
P/FCF Ratio-3.22
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue33.99
Enterprise Value/Gross Profit36.12
Enterprise Value/Ebitda-6.85
Forecast
1Y Price Target
$39.71Price Target Upside120.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.98
Revenue Forecast (FY)$8.11M
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPhase 3 trials in wet age-related macular degeneration are fully enrolled and set to report topline results, supporting progress toward potential approval and creating clear clinical milestones.
Pipeline ExpansionAdvancement of a Phase 3 program in diabetic macular edema to patient dosing expands Duravyu's late-stage pipeline and broadens potential market opportunities beyond wet AMD.
Regulatory PathwayAlignment of trial designs with major U.S. and European regulators and guidance that a single robust Phase 3 trial could support approval for tyrosine kinase inhibitors may streamline regulatory review for Duravyu.
Bears Say
Efficacy UncertaintyEfficacy comparisons against an undertreated control arm and overlapping outcome plots raise doubts about the magnitude of Duravyu's treatment benefit versus standard therapy.
Generalizability Of ResultsEnrollment of patients selected for high responsiveness to anti-VEGF raises concern that trial outcomes may not translate to the broader patient population who most need long-lasting therapies.
Safety RisksHigher rates of eye-related adverse events, including intraocular inflammation, floaters, and cataract progression, could hinder physician adoption compared with current standard therapies.
EyePoint Pharmaceuticals News
EYPT FAQ
What was EyePoint Pharmaceuticals Inc’s price range in the past 12 months?
EyePoint Pharmaceuticals Inc lowest stock price was $3.91 and its highest was $19.11 in the past 12 months.
What is EyePoint Pharmaceuticals Inc’s market cap?
EyePoint Pharmaceuticals Inc’s market cap is $1.52B.
When is EyePoint Pharmaceuticals Inc’s upcoming earnings report date?
EyePoint Pharmaceuticals Inc’s upcoming earnings report date is May 06, 2026 which is in 62 days.
How were EyePoint Pharmaceuticals Inc’s earnings last quarter?
EyePoint Pharmaceuticals Inc released its earnings results on Mar 04, 2026. The company reported -$0.81 earnings per share for the quarter, missing the consensus estimate of -$0.748 by -$0.062.
Is EyePoint Pharmaceuticals Inc overvalued?
According to Wall Street analysts EyePoint Pharmaceuticals Inc’s price is currently Undervalued.
Does EyePoint Pharmaceuticals Inc pay dividends?
EyePoint Pharmaceuticals Inc does not currently pay dividends.
What is EyePoint Pharmaceuticals Inc’s EPS estimate?
EyePoint Pharmaceuticals Inc’s EPS estimate is -0.81.
How many shares outstanding does EyePoint Pharmaceuticals Inc have?
EyePoint Pharmaceuticals Inc has 82,787,220 shares outstanding.
What happened to EyePoint Pharmaceuticals Inc’s price movement after its last earnings report?
EyePoint Pharmaceuticals Inc reported an EPS of -$0.81 in its last earnings report, missing expectations of -$0.748. Following the earnings report the stock price went down -1.747%.
Which hedge fund is a major shareholder of EyePoint Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in EYPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EyePoint Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.71 (120.61% Upside)
$39.71 (120.61% Upside)
Blogger Sentiment
Bullish
EYPT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 200.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 5.2%
Last 30 Days ▲ 5.2%
News Sentiment
Very Bullish
Bullish news 83%
Bearish news 17%
Bearish news 17%
Technicals
SMA
Positive
20 days / 200 days
Momentum
196.05%
12-Months-Change
Fundamentals
Return on Equity
-72.19%
Trailing 12-Months
Asset Growth
-13.02%
Trailing 12-Months
Company Description
EyePoint Pharmaceuticals Inc
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
EYPT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a constructive clinical and commercial story centered on rapid Phase 3 progress (wet AMD readouts mid-2026, DME pivotal dosing underway), a differentiated multi-mechanistic asset with promising Phase 2 efficacy and a clean safety profile in ~190 patients, along with manufacturing and commercial hires to support a potential launch. Offsetting these positives are material financial headwinds from sharply lower quarter and year revenues, substantially higher operating expenses and an increased net loss, with cash down year-over-year though raised financing provides runway into 2027. Regulatory/commercial execution and continued safety monitoring remain key near-term risks. Overall, the positive clinical momentum and adequate near-term funding tip the balance toward a favorable outlook despite clear financial burn and execution risks.View all EYPT earnings summariesEYPT Stock 12 Month Forecast
Average Price Target
$39.71
▲(120.61% Upside)
Technical Analysis
Urogen Pharma
―
Meiragtx Holdings
―
Stoke Therapeutics
―
Tango Therapeutics
―
Pharming Group
―
Ownership Overview
10.89% Insiders
16.39% Mutual Funds
9.51% Other Institutional Investors
51.99% Public Companies and
Individual Investors